Clinical Trial: NCT02974738
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Information Provided By: | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Last Update Posted: | 2026-09-16 |
Study Overview
Brief Summary
The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors
Official Title
A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors
Conditions
Advanced Solid Tumors, Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, ccRCC, RCC, Clear Cell Adenocarcinoma, RCC, Kidney Cancer, Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Metastatic, Renal Cell Carcinoma Recurrent, Renal Cell Carcinoma, Clear Cell Adenocarcinoma, Glioblastoma, Glioblastoma, Adult, GBM, Glioblastoma Multiforme
Intervention / Treatment
- Drug: Belzutifan
Other Study ID Numbers
- 6482-001
- PT2977-101
- MK-6482-001
Start Date (Actual)
2016-12-07
Primary Completion Date (Actual)
2018-01-12
Study Completion Date (Estimated)
2026-10-08
Enrollment (Actual)
120
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Information Provided By: | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Last Update Posted: | 2026-09-16 |
Study Overview
Brief Summary
The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors
Official Title
A Phase 1, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors
Conditions
Advanced Solid Tumors, Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, ccRCC, RCC, Clear Cell Adenocarcinoma, RCC, Kidney Cancer, Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Metastatic, Renal Cell Carcinoma Recurrent, Renal Cell Carcinoma, Clear Cell Adenocarcinoma, Glioblastoma, Glioblastoma, Adult, GBM, Glioblastoma Multiforme
Intervention / Treatment
- Drug: Belzutifan
Other Study ID Numbers
- 6482-001
- PT2977-101
- MK-6482-001
Start Date (Actual)
2016-12-07
Primary Completion Date (Actual)
2018-01-12
Study Completion Date (Estimated)
2026-10-08
Enrollment (Actual)
120
Study Type
Interventional
Phase
Phase 1